$0.548
+0.011 (+1.97%)收盤時
MBIO 資訊
MBIO 事件
Mustang Bio granted orphan drug designation by FDA for MB-101
Mustang Bio announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Mustang for MB-101 for the treatment of recurrent diffuse and anaplastic astrocytoma and glioblastoma.
Mustang Bio regains compliance with Nasdaq requirement
Mustang Bio announced that it has received notice from Nasdaq informing the company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1).
Mustang Bio exits lease for Massachusetts facility, divests equipment
Mustang Bio (MBIO) announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center (ABBV), for $1.0M. Mustang has relocated its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts. Mustang expects to continue to rely on its academic partners and future contract manufacturing relationships to support clinical trials. As a result of the termination of its lease, the company expects savings of approximately $2M of cash expenses related to the lease over the next 24 months.
Mustang Bio regains compliance with Nasdaq
Mustang Bio announced that it has received notice from Nasdaq informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。